PHOTOCURE COMPANY PRESENTATION. March 2018

Transcription

1 PHOTOCURE COMPANY PRESENTATION March 2018

2 DISCLAIMER The information included in this Presentation contains certain forward-looking statements that address activities, events or developments that Photocure ASA ( the Company ) expects, projects, believes or anticipates will or may occur in the future. These statements are based on various assumptions made by the Company, which are beyond its control and are subject to certain additional risks and uncertainties. The Company is subject to a large number of risk factors including but not limited to economic and market conditions in the geographic areas and markets where Photocure is or will be operating, IP risks, clinical development risks, regulatory risks, fluctuations in currency exchange rates, and changes in governmental regulations. For a further description of other relevant risk factors we refer to Photocure s Annual Report for As a result of these and other risk factors, actual events and our actual results may differ materially from those indicated in or implied by such forward-looking statements. The reservation is also made that inaccuracies or mistakes may occur in this information given above about current status of the Company or its business. Any reliance on the information above is at the risk of the reader, and Photocure disclaims any and all liability in this respect. 2

3 PHOTOCURE AT A GLANCE OSLO (HQ) PRINCETON, NJ Norwegian commercial-stage company focused on bladder cancer. Own commercial operations in Nordics and USA. Partners in Europe, Canada, Australia and New Zealand. 65 EMPLOYEES NORWAY SWEDEN DENMARK FINLAND U.S.A. CORE PRODUCT ON MARKET: Bladder cancer detection & management 2017 REVENUES $20 US MILLION ON OSLO STOCK EXCHANGE SINCE

4 TRANSFORMING BLADDER CANCER MANAGEMENT INNOVATIVE PRODUCTS drugs medical devices diagnostics KNOWLEDGE bladder cancer expertise end-to-end insight Transformative solutions for Bladder Cancer Urology providers Improved outcomes for patients 4

5 STRATEGIC FOCUS ON EXPANDING BLADDER CANCER OFFERINGS CORE PRODUCT ON MARKET: NEW CORE PRODUCTS: NON-CORE PIPELINE PRODUCTS: Complementary, within bladder cancer Visonac (Acne treatment) Cevira (Cervical disease treatment) Bladder cancer detection & management Focus next 1 2 years Growth in existing markets Expansion into flexible cystoscopy market Expansion into new markets Expansion of portfolio Partner out Assess partnering opportunities and strategic alternatives 5

6 LARGE UNMET NEEDS IN NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) COMMON 9 th most common cancer worldwide RECURRING 61% recurrence in 1 year new cases 78% recurrence in 5 years deaths annually 75% are men EXPENSIVE #1 Highest per patient lifetime treatment costs of any cancer Main cost drivers are TURBT with anesthesia and hospitalization DEBILITATING Lifelong follow-up with repeat TURBTs and cystoscopies Potential urinary dysfunction, patient fear, anxiety and confusion?

7 BLUE LIGHT CYSTOSCOPY WITH HEXVIX /CYSVIEW CONFIDENCE AT FIRST SIGHT STANDARD WHITE LIGHT BLC WITH HEXVIX/CYSVIEW Detect improves detection of bladder lesions and the accuracy of diagnosis right from the start Treat ensures more complete removal of bladder tumors, reduced recurrence risk, and improved patient outcomes Control gives patient, physician and payer confidence in improved management decisions Use in all patients at the first TURBT, first follow up, and in the ongoing management of intermediate and high risk patients Recommended in key guidelines and expert recommendations patients treated with Hexvix /Cysview 7

8 BLUE LIGHT CYSTOSCOPY WITH HEXVIX /CYSVIEW IMPROVED DETECTION FOR BETTER OUTCOMES PATIENT SYMPTOMS GP Urine tests FIRST DIAGNOSTIC CYSTOSCOPY Outpatient/Office Flexible scopes TURBT Operating room/day surgery Rigid scopes SURVEILLANCE CYSTOSCOPY Outpatient/Office Flexible scopes THE HEXVIX/CYSVIEW ADVANTAGE Improved detection Complete tumor removal Reduced recurrence and progression Cost benefits Better management 8

9 CEVIRA AND VISONAC NON-CORE PRODUCTS THAT ADDRESS MAJOR OPPORTUNITIES CEVIRA CERVICAL CANCER Potential to fill high unmet need for non-surgical treatment of HPV/CIN populations Breakthrough, single use, integrated drugdevice technology Easy and convenient for provider and patient Phase 3 ready Solid Phase 2b trial results in HSIL patients Blockbuster sales potential based on premium pricing opportunity Assessing strategic alternatives and partnership opportunities VISONAC ACNE 9 Potential to fill high unmet medical need for nonantibiotic, non-retinoid treatment in severe acne population Photodynamic therapy (PDT): application of Visonac cream plus red light illumination Positive Phase 2b results published in British Journal of Dermatology Phase 3 ready, with significantly reduced regulatory risk Reviewing strategic alternatives and partner opportunities

10 OUR CORPORATE VALUES GUIDE OUR BEHAVIOR: CARE, COURAGE AND PASSION CARE Behave respectfully Act professionally Utilize diversity Support to succeed COURAGE Dare to trust Be transparent Challenge to improve Be gutsy PASSION Embrace creativity Inspire your colleagues Walk the extra mile Have fun! 10

11 11 Thank you for your attention